Abstract
A rarely reported phenomenon of rapid-tempo puberty in which the physical changes of puberty and testosterone levels increase very rapidly has not been reported outside apart from in two reviews. The resulting rapid advancement of skeletal age causes early completion of growth with shorter adult stature than expected. This appears to be genetic given its occurrence in the present report in two families, one with three brothers, one with two. We also describe potential treatments and found for the youngest that early initiation of standard therapy preserved or reclaimed adult height (AH) potential. The foreshortened AH in this situation involves rapidly advancing puberty resulting from high circulating testosterone levels leading to rapid advance in skeletal age. This was recognized earlier among younger brothers and treatment with gonadotropin-releasing analogues, growth hormone (GH) and/or aromatase inhibitor therapy (AIT) was tried. Two brothers in family A and family B were treated. Case 5 started treatment early enough so his AH was within target height (mid-parental height) range. Cases 2, 3, 4 were tried on GH and/or AIT with outcomes suggesting benefit. The prevalence and mechanism of rapid-tempo puberty requires further study. Furthermore, as illustrated by two of the current cases, this phenomenon may have a heightened prevalence, or at least may occur, in children previously diagnosed with constitutional delay of growth, underscoring the need to be cautious in assurance of a normal AH outcomes in this population, based on data from a single assessment.
Keywords: Short adult height, rapid-tempo puberty, male-limited genetic pubertal trait, gonadotropin-releasing hormone analogue, growth hormone, aromatase inhibitor therapy
Read the full text
3 sections · 3 figures · 1 table · PDF
Create your free account to read the full text.
- Full text with figures and tables
- PDF and supplementary files
- Access on every Galenos journal
One Galenos account works on every Galenos journal site.
References
Geffner M. Variations in tempo of normal pubertal progression. Pediatric Endocrinol Rev 2007;4(Suppl 3):278-282.
Bakhtiani P, Geffner M. Early Puberty. Pediatr Rev 2022;43:483-492.
Mauras N, Ross J, Mericq V. Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review. Endocr Rev 2023;44:1-13.
Wit JM. Should Skeletal Maturation Be Manipulated for Extra Height Gain? Front Endocrinol (Lausanne) 2021;12:812196.
Banerjee S, Bajpai A. Precocious Puberty. Indian J Pediatr 2023;90:582-589. Epub 2023 Apr 19
Leschek EW, Flor AC, Bryant JC, Jones JV, Barnes KM, Cutler GB Jr. Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty. J Pediatr 2017;190:229-235.
Lazar L, Levy S, Oron T, Meyerovitch J, de Vries L, Shalitin S, Tenenbaum A, Phillip M, Lebenthal Y. The Beneficial Effect of Combined GH/GnRHa Therapy in Increasing Adult Height Outcome in Children With ISS. J Clin Endocrinol Metab 2019;104:3287-3295.
van der Steen M, Lem AJ, van der Kaay DC, Hokken-Koèelega AC. Puberty and Pubertal Growth in GH-treated SGA Children: Effects of 2 Years of GnRHa Versus No GnRHa. J Clin Endocrinol Metab 2016;101:2005-2012. Epub 2016 Mar 10
Hokken-Koelega ACS, van der Steen M, Boguszewski MCS, Cianfarani S, Dahlgren J, Horikawa R, Mericq V, Rapaport R, Alherbish A, Braslavsky D, Charmandari E, Chernausek SD, Cutfield WS, Dauber A, Deeb A, Goedegebuure WJ, Hofman PL, Isganatis E, Jorge AA, Kanaka-Gantenbein C, Kashimada K, Khadilkar V, Luo XP, Mathai S, Nakano Y, Yau M. International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood. Endocr Rev 2023;44:539-565.
Post EM, Richman RA. A condensed table for predicting adult stature. J Pediatr 1981;98:440-442.
Dotremont H, France A, Heinrichs C, Tenoutasse S, Brachet C, Cools M, De Waele K, Massa G, Lebrethon MC, Gies I, Van Besien J, Derycke C, Ziraldo M, De Schepper J, Beauloye V, Verhulst S, Rooman R, den Brinker M. Efficacy and safety of a 4-year combination therapy of growth hormone and gonadotropin-releasing hormone analogue in pubertal girls with short predicted adult height. Front Endocrinol (Lausanne) 2023;14:1113750.
Saggese G, Federico G, Barsanti S, Cerri S. Is there a place for combined therapy with GnRH agonist plus growth hormone in improving final height in short statured children? J Pediatr Endocrinol Metab 2000;13(Suppl 1):821-826.
